Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes.

Mulder S, Hammarstedt A, Nagaraj SB, Nair V, Ju W, Hedberg J, Greasley PJ, Eriksson JW, Oscarsson J, Heerspink HJL.

Diabetes Obes Metab. 2020 Mar 1. doi: 10.1111/dom.14018. [Epub ahead of print]

PMID:
32115853
2.

BMP4 gene therapy enhances insulin sensitivity but not adipose tissue browning in obese mice.

Hoffmann JM, Grünberg JR, Hammarstedt A, Kroon T, Greiner TU, Maurer S, Elias I, Palsdottir V, Bosch F, Boucher J, Hedjazifar S, Smith U.

Mol Metab. 2020 Feb;32:15-26. doi: 10.1016/j.molmet.2019.11.016. Epub 2019 Dec 17.

3.

Characterization of Human Induced Pluripotent Stem Cell-Derived Hepatocytes with Mature Features and Potential for Modeling Metabolic Diseases.

Holmgren G, Ulfenborg B, Asplund A, Toet K, Andersson CX, Hammarstedt A, Hanemaaijer R, Küppers-Munther B, Synnergren J.

Int J Mol Sci. 2020 Jan 11;21(2). pii: E469. doi: 10.3390/ijms21020469.

4.

The Novel Adipokine Gremlin 1 Antagonizes Insulin Action and Is Increased in Type 2 Diabetes and NAFLD/NASH.

Hedjazifar S, Khatib Shahidi R, Hammarstedt A, Bonnet L, Church C, Boucher J, Blüher M, Smith U.

Diabetes. 2020 Mar;69(3):331-341. doi: 10.2337/db19-0701. Epub 2019 Dec 27.

PMID:
31882566
5.

Adipose tissue dysfunction is associated with low levels of the novel Palmitic Acid Hydroxystearic Acids.

Hammarstedt A, Syed I, Vijayakumar A, Eliasson B, Gogg S, Kahn BB, Smith U.

Sci Rep. 2018 Oct 25;8(1):15757. doi: 10.1038/s41598-018-34113-3.

6.

Impaired Adipogenesis and Dysfunctional Adipose Tissue in Human Hypertrophic Obesity.

Hammarstedt A, Gogg S, Hedjazifar S, Nerstedt A, Smith U.

Physiol Rev. 2018 Oct 1;98(4):1911-1941. doi: 10.1152/physrev.00034.2017. Review.

7.

A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes.

van Zuydam NR, Ahlqvist E, Sandholm N, Deshmukh H, Rayner NW, Abdalla M, Ladenvall C, Ziemek D, Fauman E, Robertson NR, McKeigue PM, Valo E, Forsblom C, Harjutsalo V; Finnish Diabetic Nephropathy Study (FinnDiane), Perna A, Rurali E, Marcovecchio ML, Igo RP Jr, Salem RM, Perico N, Lajer M, Käräjämäki A, Imamura M, Kubo M, Takahashi A, Sim X, Liu J, van Dam RM, Jiang G, Tam CHT, Luk AOY, Lee HM, Lim CKP, Szeto CC, So WY, Chan JCN; Hong Kong Diabetes Registry Theme-based Research Scheme Project Group, Ang SF, Dorajoo R, Wang L, Clara TSH, McKnight AJ, Duffy S; Warren 3 and Genetics of Kidneys in Diabetes (GoKinD) Study Group, Pezzolesi MG; GENIE (GEnetics of Nephropathy an International Effort) Consortium, Marre M, Gyorgy B, Hadjadj S, Hiraki LT; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group, Ahluwalia TS, Almgren P, Schulz CA, Orho-Melander M, Linneberg A, Christensen C, Witte DR, Grarup N, Brandslund I, Melander O, Paterson AD, Tregouet D, Maxwell AP, Lim SC, Ma RCW, Tai ES, Maeda S, Lyssenko V, Tuomi T, Krolewski AS, Rich SS, Hirschhorn JN, Florez JC, Dunger D, Pedersen O, Hansen T, Rossing P, Remuzzi G; SUrrogate markers for Micro- and Macrovascular hard endpoints for Innovative diabetes Tools (SUMMIT) Consortium, Brosnan MJ, Palmer CNA, Groop PH, Colhoun HM, Groop LC, McCarthy MI.

Diabetes. 2018 Jul;67(7):1414-1427. doi: 10.2337/db17-0914. Epub 2018 Apr 27.

8.

TP53INP2 regulates adiposity by activating β-catenin through autophagy-dependent sequestration of GSK3β.

Romero M, Sabaté-Pérez A, Francis VA, Castrillón-Rodriguez I, Díaz-Ramos Á, Sánchez-Feutrie M, Durán X, Palacín M, Moreno-Navarrete JM, Gustafson B, Hammarstedt A, Fernández-Real JM, Vendrell J, Smith U, Zorzano A.

Nat Cell Biol. 2018 Apr;20(4):443-454. doi: 10.1038/s41556-018-0072-9. Epub 2018 Mar 28.

PMID:
29593329
9.

CCN5/WISP2 and metabolic diseases.

Grünberg JR, Elvin J, Paul A, Hedjazifar S, Hammarstedt A, Smith U.

J Cell Commun Signal. 2018 Mar;12(1):309-318. doi: 10.1007/s12079-017-0437-z. Epub 2017 Dec 15. Review.

10.

Epigenetic modifications of the Zfp/ZNF423 gene control murine adipogenic commitment and are dysregulated in human hypertrophic obesity.

Longo M, Raciti GA, Zatterale F, Parrillo L, Desiderio A, Spinelli R, Hammarstedt A, Hedjazifar S, Hoffmann JM, Nigro C, Mirra P, Fiory F, Formisano P, Miele C, Smith U, Beguinot F.

Diabetologia. 2018 Feb;61(2):369-380. doi: 10.1007/s00125-017-4471-4. Epub 2017 Oct 24.

11.

BMP4 Gene Therapy in Mature Mice Reduces BAT Activation but Protects from Obesity by Browning Subcutaneous Adipose Tissue.

Hoffmann JM, Grünberg JR, Church C, Elias I, Palsdottir V, Jansson JO, Bosch F, Hammarstedt A, Hedjazifar S, Smith U.

Cell Rep. 2017 Aug 1;20(5):1038-1049. doi: 10.1016/j.celrep.2017.07.020.

12.

Metabolic characteristics of individuals at a high risk of type 2 diabetes - a comparative cross-sectional study.

Henninger J, Rawshani A, Hammarstedt A, Eliasson B.

BMC Endocr Disord. 2017 Jul 14;17(1):40. doi: 10.1186/s12902-017-0191-5.

13.

Increased adipose tissue aromatase activity improves insulin sensitivity and reduces adipose tissue inflammation in male mice.

Ohlsson C, Hammarstedt A, Vandenput L, Saarinen N, Ryberg H, Windahl SH, Farman HH, Jansson JO, Movérare-Skrtic S, Smith U, Zhang FP, Poutanen M, Hedjazifar S, Sjögren K.

Am J Physiol Endocrinol Metab. 2017 Oct 1;313(4):E450-E462. doi: 10.1152/ajpendo.00093.2017. Epub 2017 Jun 27.

14.

Cephalic phase of insulin secretion in response to a meal is unrelated to family history of type 2 diabetes.

Eliasson B, Rawshani A, Axelsen M, Hammarstedt A, Smith U.

PLoS One. 2017 Mar 13;12(3):e0173654. doi: 10.1371/journal.pone.0173654. eCollection 2017.

15.

Overexpressing the novel autocrine/endocrine adipokine WISP2 induces hyperplasia of the heart, white and brown adipose tissues and prevents insulin resistance.

Grünberg JR, Hoffmann JM, Hedjazifar S, Nerstedt A, Jenndahl L, Elvin J, Castellot J, Wei L, Movérare-Skrtic S, Ohlsson C, Holm LM, Bäckhed F, Syed I, Bosch F, Saghatelian A, Kahn BB, Hammarstedt A, Smith U.

Sci Rep. 2017 Feb 27;7:43515. doi: 10.1038/srep43515.

16.

Metabolic predictors of impaired glucose tolerance and type 2 diabetes in a predisposed population--A prospective cohort study.

Henninger J, Hammarstedt A, Rawshani A, Eliasson B.

BMC Endocr Disord. 2015 Sep 25;15:51. doi: 10.1186/s12902-015-0048-8.

17.

Insulin resistance and impaired adipogenesis.

Gustafson B, Hedjazifar S, Gogg S, Hammarstedt A, Smith U.

Trends Endocrinol Metab. 2015 Apr;26(4):193-200. doi: 10.1016/j.tem.2015.01.006. Epub 2015 Feb 18. Review.

PMID:
25703677
18.

BMP4 and BMP Antagonists Regulate Human White and Beige Adipogenesis.

Gustafson B, Hammarstedt A, Hedjazifar S, Hoffmann JM, Svensson PA, Grimsby J, Rondinone C, Smith U.

Diabetes. 2015 May;64(5):1670-81. doi: 10.2337/db14-1127. Epub 2015 Jan 20.

19.

Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures.

Movérare-Skrtic S, Henning P, Liu X, Nagano K, Saito H, Börjesson AE, Sjögren K, Windahl SH, Farman H, Kindlund B, Engdahl C, Koskela A, Zhang FP, Eriksson EE, Zaman F, Hammarstedt A, Isaksson H, Bally M, Kassem A, Lindholm C, Sandberg O, Aspenberg P, Sävendahl L, Feng JQ, Tuckermann J, Tuukkanen J, Poutanen M, Baron R, Lerner UH, Gori F, Ohlsson C.

Nat Med. 2014 Nov;20(11):1279-88. doi: 10.1038/nm.3654. Epub 2014 Oct 12.

20.

Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects.

Yore MM, Syed I, Moraes-Vieira PM, Zhang T, Herman MA, Homan EA, Patel RT, Lee J, Chen S, Peroni OD, Dhaneshwar AS, Hammarstedt A, Smith U, McGraw TE, Saghatelian A, Kahn BB.

Cell. 2014 Oct 9;159(2):318-32. doi: 10.1016/j.cell.2014.09.035.

Supplemental Content

Loading ...
Support Center